Clinical trial

A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

NCT03819465

Drugs and interventions used in this trial

10 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Durvalumab Normalized identity: durvalumabView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Danvatirsen Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Oleclumab Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention MEDI5752 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Pemetrexed Normalized identity: pemetrexedView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Carboplatin Normalized identity: carboplatinView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Gemcitabine Normalized identity: gemcitabineView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Cisplatin Normalized identity: cisplatinView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Nab-paclitaxel Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention AZD2936 Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2018-12-27

PhasePHASE1

Conditions

Metastatic Non-Small Cell Lung Cancer (NSCLC)unresolved

Interventions

DurvalumabDRUG · verified · RxNorm: durvalumab

DanvatirsenDRUG

OleclumabDRUG

MEDI5752DRUG

PemetrexedDRUG · verified · RxNorm: pemetrexed

CarboplatinDRUG · verified · RxNorm: carboplatin

GemcitabineDRUG · verified · RxNorm: gemcitabine

CisplatinDRUG · verified · RxNorm: cisplatin

Nab-paclitaxelDRUG

AZD2936DRUG

Sponsors & collaborators

AstraZenecalead sponsor

Mapped research locations

SeoulSouth Korea4 TaipeiTaiwan3 MadridSpain2 BarcelonaSpain2 Saint PetersburgRussia2 TaichungTaiwan2 BangkokThailand2 NashvilleTennessee, United States1 PittsburghPennsylvania, United States1 MoscowRussia1 WarsawPoland1 SevilleSpain1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03819465 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.